Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Current affairs: opinion on quizartinib approval status in AML

Mark Levis • 15 Jun 2019
EHA 2019
Acute Myeloid Leukemia Leukemia Quizartinib
QuANTUM-First QuANTUM-R

Mark Levis, MD, PhD, from the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the current status of quizartinib monotherapy for FLT3+ relapsed/refractory acute myeloid leukemia (AML) following the results of the QuANTUM-R trial (NCT02039726). He also expresses his excitement about the devlopment of the QuANTUM-First trial (NCT02668653). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Mark Levis

Updates on the QuANTUM-First trial: quizartinib plus chemotherapy in newly diagnosed FLT3m AML
0:46
Updates on the QuANTUM-First trial: quizartinib plus chemotherapy in newly diagnosed FLT3m AML
Mark Levis • 12 Jun 2026
The impact of prior induction cycle number on outcomes with gilteritinib in R/R FLT3-mutated AML
0:53
The impact of prior induction cycle number on outcomes with gilteritinib in R/R FLT3-mutated AML
Mark Levis • 12 Jun 2026
Datasets at ASH 2025 that will refine the management of FLT3-mutated AML
1:39
Datasets at ASH 2025 that will refine the management of FLT3-mutated AML
Mark Levis • 5 Dec 2025
Understanding the results of MORPHO: gilteritinib as post-transplant maintenance for FLT3-ITD AML
2:03
Understanding the results of MORPHO: gilteritinib as post-transplant maintenance for FLT3-ITD AML
Mark Levis • 5 Dec 2025

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals